1. Executive Summary (Confidence: High)

Oncobit, founded in 2018 as a spin-off from the University of Zurich, represents a sophisticated advancement in the longevity ecosystem by targeting cancer—a primary contributor to biological decay and age-related mortality.^[1] The organization has positioned itself at the forefront of the precision medicine movement, specifically focusing on the detection and quantification of circulating tumor DNA (ctDNA) through a minimally invasive liquid biopsy approach.^[3] By bridging the gap between high-complexity genomics and routine clinical practice, Oncobit provides standardized, data-driven solutions that allow for the longitudinal monitoring of oncological patients.^[3] With a total funding base of approximately $14.9 million and a recent Series A expansion, the company has transitioned from a research-centric entity to a commercial-stage diagnostic provider with significant regulatory milestones, including CE-IVDR certification.^[6] The executive leadership, guided by CEO Dr. Claudia Scheckel, has strategically established partnerships with international leaders such as ID Solutions and TrilliumBiO to facilitate decentralized testing in Europe and market entry in the United States, underscoring its role as a scalable infrastructure provider in the global fight against solid tumors.^[4]